Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier: Preparation and trypanocidal activity

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 49, Issue 2, 2000, Pages 137-142

  González Martín, Guillermo ^a   Figueroa, Claudia ^a   Merino, Isabel ^a   Osuna, Antonio ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Allopurinol; Drug carrier; Nanoparticles; Polycyanoacrylates; Trypanosoma cruzi

Indexed keywords

ALLOPURINOL; NANOPARTICLE; POLY(ETHYL 2 CYANOACRYLATE);

ANTIMICROBIAL ACTIVITY; ARTICLE; CYTOMETRY; DRUG FORMULATION; DRUG SYNTHESIS; ELECTRON MICROSCOPY; EPIMASTIGOTE; POLYMERIZATION; TRYPANOSOMA CRUZI;

ADSORPTION; ALLOPURINOL; ANIMALS; CYANOACRYLATES; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 0342614966     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(99)00076-4     Document Type: Article

References (30)

1. WHO Technical Reports Series, 202 (1960).
2. Schenone H., Villarroel F., Rojas A., Alfaro E. Factores biológicos y ecológicos de la enfermedad de Chagas en Chile. Bol. Chileno Parasitol. 35:1980;42-54.
3. Brener Z. Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the western Hemisphere. Pharmacol. Ther. 7:1979;71-90.
4. Levi G.C., Amato V. Neto, J.F.De Araujo, Analise de manisfestacoes colaterais devidas ao uso do medicamento Ro-7-1051 nitromidazolico especifico da doenca de Chagas. Rev. Inst. Med. Trop. Sao Paulo. 17:1975;49-52.
5. Gutteridge W.E. Chemotherapy of Chagas' disease. Trans. R. Soc. Trop. Med. Hyg. 70:1976;123-124.
6. Avila J.L., Avila A., Muñoz E. Effect of allopurinol on different strains of Trypanosoma cruzi. Am. J. Trop. Med. Hyg. 30:1981;769-774.
7. Berens R.L., Marr J.J., Steele F.S. da Cruz. D.J. Nelson, Effect of allopurinol on Trypanosoma cruzi: metabolism and biological activity in intracellular and bloodstream forms. Antimicrob. Agents Chemother. 22:1982;657-661.
8. Berens R.L., Marr J.J., Looker D.L., Nelson D.L., LaFon S.W. Efficacy of pyrazolopyrimidine ribonucleosides against Trypanosoma cruzi: studies in vitro and in vivo with sensitive and resistent strains. J. Infect. Dis. 150:1984;602-608.
9. Fish W.R., Marr J.J., Berens R.L., Looker D.L., Nelson D.L., LaFon S.W., Balber A.E. Inosine analogs as chemotherapuetics agents for African trypanosomes: metabolism in trypanosomes and efficacy in tissue culture. Antimicrob. Agents Chemother. 27:1985;33-36.
10. Marr J.J., Berens R.L., Cohn N.K., Nelson D.J., Klein R.S. Biological action of inosine analogs in Leishmania and Trypanosome species. Antimicrob. Agents Chemother. 25:1984;292-295.
11. Nakajima-Shimada J., Hirota Y., Aoki T. Inhibition of Trypanosoma cruzi growth in mammalian cells by purine and pyrimidine analogs. Antimicrob. Agents Chemother. 40:1996;2455-2458.
12. Avila J.L., Avila A. Trypanosoma cruzi: allopurinol in the treatment of mice with experimental acute Chagas' disease. Exp. Parasitol. 51:1981;204-208.
13. Castrillon-Rivera L.E., García-Fernández W., Pérez-Fernández L., Gutierrez C. Efecto terapéutico de allopurinol en el ratón cepa CFW con tripanosomiasis americana (Enfermedad de Chagas). Salud Púb. Mex. 2:1984;146-154.
14. Gallerano R.H., Marr J.J., Sosa R.R. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. Am. J. Trop. Med. Hyg. 43:1990;159-166.
15. Almeida D.R., Carvalho A.C., Branco J.N., Pereira A.P., Correa L., Vianna P.V., Buffolo E., Martínez E.E. Chagas' disease reactivation after heart transplantation: efficacy of allopurinol treatment. J. Heart Lung Transplant. 15:1996;988-992.
16. Apt W., Aguilera X., Arribada A., Pérez C., Miranda C., Cortés P., Rodríguez J. Treatment of chronic Chagas' disease with itraconazole and allopurinol: preliminary report. Rev. Méd. Chile. 122:1994;420-427.
17. de Castro S.L. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Trop. 53:1993;83-98.
18. Martínez S., Marr J.J. Allopurinol in the treatment of Americans leishmaniasis. N. Engl. J. Med. 326:1992;741-744.
19. Gallerano R.H., Sosa R.R. Efecto antiparasitario del allopurinol en la enfermedad de Chagas crónico. Medicina. 45:1985;697-698.
20. Gallerano R.H., Sosa R.R. Tratamiento de pacientes chagásicos con xenodiagnóstico positivo. Efectos del nifurtimox, benznidazol, y allopurinol. Rev. Fed. Arg. Cardiol. XIV:1985;119-123.
21. Sosa R.R., Gallerano R.H. Tratamiento de la enfermedad de Chagas crónico. Efectos del allopurinol. Rev. Fed. Arg. Cardiol. 17:1988;234-236.
22. Gonzalez-Martin G., Merino I., Rodríguez-Cabezas N., Torres M., Nuñez R., Osuna A. Characterization and Trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates. J. Pharm. Pharmacol. 50:1998;29-35.
23. Couvreur P., Lenaerts V., Leyh D., Guiot M., Roland M. Design of biodegradable polyalkylcyanoacrylate nanoparticles as a drug carrier. Davis S.S., Illum L., Mac Vie J.G., Tomlinson E. Microspheres and Drug Therapy Pharmaceutical Immunological and Medical Aspects. 1984;103-114 Elsevier, Amsterdam.
24. Cicek H., Puncel A., Puncel M., Piskin E. Degradation and drug release characteristics of monosize polyethylcyanoacrylate microspheres. J. Biomater. Sci. Polymer. Educ. 6:1994;845-856.
25. Yang H.C., Nemoto Y., Homma T., Matsuoka H., Yamada S., Sumita O., et al. Curr. Microbiol. 30:1995;173-176.
26. Wade C.W., Leonard F. Degradation of poly(methyl 2-cyanoacrylates). J. Biomed. Mater. Res. 6:1972;215-220.
27. Tseng Y.C., Tabata Y., Hyon S.H., Ikada Y. In vitro toxicity test of 2-cyanoacrylate polymers by cell culture method. J. Biomed. Mater. Res. 24:1990;1355-1367.
28. Lenaerts V., Couvreur P., Christiaens-Leyh D., Joiris E., Roland M., Rollman B., Speiser P. Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials. 5:1984;65-68.
29. Fresta M., Puglis G., Giammona G., Cavallaro G., Micali N., Furner P.M. Pefloxacine mesilate and Ofloxacin loaded polyethylcyanoacrylate nanoparticles: characterization of the colloidal drug carrier formulation. J. Pharm. Sci. 84:1995;895-902.
30. Lherm C., Couvreur P., Loiseau P., Bories C., Gayral P. Unloaded polyisobutylcyanoacrylate nanoparticles: efficiency against bloodstream trypanosomes. J. Pharm. Pharmacol. 39:1987;650-652.